• Who We Are
    • About Us
    • Contact Us
    • Member Partners
  • News
    • Latest News
    • Letters
    • Newsletters
    • Press Releases
    • Recent Events
  • The Issue
    • Interchangeable Biosimilars
    • Inflation Reduction Act (IRA)
    • Naming
    • Biologic Safety
    • BIO Principles
    • Non-Medical Switching
  • Policy
    • Australia
    • Canada
    • FDA
    • FDA Guidance
    • In the States
  • Resources
    • Surveys
    • Courses
    • Webinars
    • Approvals
    • Whitepapers
  • Blog
  • Videos

Safe Biologics

  • Safe Biologics

  • Who We Are
    • About Us
    • Contact Us
    • Member Partners
  • News
    • Latest News
    • Letters
    • Newsletters
    • Press Releases
    • Recent Events
  • The Issue
    • Interchangeable Biosimilars
    • Inflation Reduction Act (IRA)
    • Naming
    • Biologic Safety
    • BIO Principles
    • Non-Medical Switching
  • Policy
    • Australia
    • Canada
    • FDA
    • FDA Guidance
    • In the States
  • Resources
    • Surveys
    • Courses
    • Webinars
    • Approvals
    • Whitepapers
  • Blog
  • Videos
Background Image

Biotechnology Institute
Chesapeake Bioscience Education Foundation
Northern Virginia Life Sciences Communities
Virginia Bioscience Legislative Caucus
Virginia Biotechnology Association
Virginia Biotechnology Center
Virginia Council on Advanced Technology Skills
Virginia Department of Health
Virginia General Assembly
Virginia Tech Department of Biological Sciences
Virginia Tech Fralin Life Science Institute
Medical Society of Virginia
Office of Governor Bob McDonnell
University of Virginia Research Park
VCU Life Sciences

Latest News

Trust is Built on Data: Preserving the FDA’s Evidence-Based Approach to Interchangeable Biosimilars

By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) In a recent CBS News interview, newly appointed FDA Commissioner Dr. Marty Makary called for more robust clinical evidence before recommending the latest COVID-19 booster shots. “There’s a void of data,” Dr. Makary said, underscoring a renewed focus on restoring public trust through a […]

Read More

Statement from the ASBM on Senate HELP Committee 340B Reform Report

April 29, 2025 The Alliance for Safe Biologic Medicines (ASBM) commends Senator Bill Cassidy and the Senate HELP Committee for their new report, “Congress Must Act to Bring Needed Reforms to the 340B Program.” The program is designed to support underserved populations by ensuring access to medicines by allowing qualifying entities to safety-net hospitals, community […]

Read More

ASBM Statement on President Trump’s Executive Order Supporting Patients Who Depend on Small-Molecule Medicines

April 21, 2025  The Alliance for Safe Biologic Medicines (ASBM) commends President Donald J. Trump for his leadership in issuing an executive order to address the harmful “pill penalty” contained within the Inflation Reduction Act (IRA). This provision, enacted during the Biden administration, imposes price controls on small-molecule medicines—commonly delivered in pill or tablet form—just […]

Read More

logo logo logo
logo

The Alliance for Safe Biologic Medicines is an organization composed of diverse healthcare groups — from patients to physicians, medical innovators, and others who are working together to ensure patient safety is at the forefront of the biosimilars policy discussion.

Contact Us

Who we are
  • About Us
  • Contact Us
  • Member Partners
  • International Advisory Board
News
  • Latest News
  • Letters
  • Newsletter
  • Press Releases
  • Recent Events
The Issue
  • Interchangeable Biosimilars
  • Inflation Reduction Act (IRA)
  • Naming
  • Substitution Policy
  • Biologic Safety
  • BIO Principles
Policy
  • Australia
  • Canada
  • European Union
  • FDA
  • FDA Guidance
  • In the States
Resources
  • Surveys
  • Courses
  • Webinars